Samsung Bioepis' Keytruda Biosimilar SB27 Shows Promising Cancer Treatment Results: Clinical Outcomes and Market Outlook
Keytruda Biosimilar SB27: Clinical Results and Market Outlook
Samsung Bioepis' biosimilar to Keytruda, 'SB27,' has demonstrated equivalent therapeutic efficacy in Phase 1 and Phase 3 clinical trials compared to Keytruda (pembrolizumab). Samsung Bioepis completed its domestic market approval application on August 10, 2026, positioning itself for competition in the approximately KRW 43 trillion market ahead of Keytruda's patent expiration, competing with Celltrion.
SB27 has gained attention as a potential alternative to Keytruda in cancer treatment. Samsung Bioepis is strengthening its R&D investments to develop next-generation Nectin-4 ADC therapies, which could offer new treatment options for cancer patients while enhancing the competitiveness of South Korea's biotechnology industry.
As Keytruda's patent expiration approaches, Samsung Bioepis has clearly outlined SB27's clinical results and approval timeline, emphasizing therapeutic efficacy and market competition dynamics. This is viewed as a significant development in the field of cancer treatment.

SB27 Clinical Results: Demonstrated Equivalence and Approval Timeline
Samsung Bioepis has demonstrated through Phase 1 and Phase 3 clinical trials that SB27 shows equivalent therapeutic efficacy to Keytruda. This meets the core benchmark for biosimilar development—'equivalence.' As reported by Hankyoreh on June 29, 2026, Samsung Bioepis publicly shared SB27's clinical results confirming this equivalence.
Subsequently, on August 10, 2026, Samsung Bioepis completed its domestic market approval application for SB27. This positions the company to secure a leading position in competition with Celltrion ahead of Keytruda's patent expiration. Major media outlets including JoongAng Ilbo and Money Today reported on August 10, 2026, about Samsung Bioepis' approval application.
SB27's clinical results were specifically validated in Phase 3 studies. Keytruda (pembrolizumab) is the world's top-selling anticancer drug, and with its patent expiration approaching, SB27 has emerged as a potential successor product. Samsung Bioepis presented SB16 and SB27 as the same product, announcing the successful completion of Keytruda biosimilar development.
Keytruda Market Competition: Samsung Bioepis vs. Celltrion Strategy
The Keytruda market is valued at approximately KRW 43 trillion, and with Keytruda's patent expiration approaching, competition between Samsung Bioepis and Celltrion has intensified. Samsung Bioepis completed its domestic market approval application for SB27, responding to Celltrion's strategy of launching a Keytruda biosimilar.
After completing the market approval application on August 10, 2026, Samsung Bioepis is strengthening R&D investments to develop next-generation therapies. This strategy is viewed as enhancing the company's long-term competitiveness. Additionally, Samsung Bioepis showcased non-clinical results at AACR 2026, demonstrating progress in Nectin-4 ADC therapy development.
Celltrion has already launched a Keytruda biosimilar, so for SB27 to compete effectively in the market, Samsung Bioepis must demonstrate faster launch strategies and therapeutic efficacy. Samsung Bioepis aims to secure a significant share of the KRW 43 trillion Keytruda market with SB27.
SB27 Therapeutic Effect: Clinical Results and Patient Application
SB27 is a biosimilar to Keytruda, demonstrating identical efficacy in cancer treatment. Phase 1 and Phase 3 clinical trials confirmed that the therapeutic effects of SB27 and Keytruda are similar, meaning it can provide patients with equivalent treatment outcomes as Keytruda.
By presenting SB27's clinical results, Samsung Bioepis has introduced a new option in cancer treatment. Particularly as Keytruda's patent expiration approaches, SB27 is gaining attention as an affordable alternative that could reduce patient financial burdens. This offers more treatment options for patients while also potentially reducing healthcare costs.
Since SB27's clinical results have demonstrated equivalent therapeutic efficacy to Keytruda, it can be used as a substitute for Keytruda in cancer patients. Samsung Bioepis aims to secure competitiveness in the domestic market through SB27 and is planning global market entry as well.
Keytruda Patent Expiration and Market Outlook
Keytruda (pembrolizumab) is the world's top-selling anticancer drug, with its patent expiration approaching. As a result, biosimilar development has accelerated, forming a competitive landscape led by Samsung Bioepis and Celltrion.
By clearly presenting SB27's clinical results and approval timeline, Samsung Bioepis emphasized its strategy for securing market leadership in the Keytruda market. This is expected to play a crucial role in gaining competitiveness in the KRW 43 trillion market.
Following Keytruda's patent expiration, it will be closely watched whether SB27 can establish itself as a substitute for Keytruda. Samsung Bioepis is strengthening R&D investments to develop next-generation therapies, which represents a strategic move to secure a favorable position in long-term market competition.
Samsung Bioepis' R&D Strategy: Development of Next-Generation Therapies
Besides SB27, Samsung Bioepis is accelerating the development of next-generation Nectin-4 ADC therapies. At AACR 2026, it publicly shared non-clinical results, showcasing its research achievements in this field.
Samsung Bioepis has stated that it will continue to lead scientific research through strengthened R&D investments. This is interpreted as a strategic move not only for the successful market entry of SB27 but also to secure long-term competitiveness in the biotechnology industry.
The development of next-generation therapies holds potential to drive new innovations in cancer treatment. Samsung Bioepis aims to provide treatment options for various types of cancer beyond the Keytruda market through this approach.
Key Information to Verify: Market Competition and Clinical Results
If SB27 is used as an alternative to Keytruda, patients can expect therapeutic effects equivalent to those provided by Keytruda. This has been confirmed in Phase 1 and Phase 3 clinical trials.
The market competition ahead of Keytruda's patent expiration involves Samsung Bioepis and Celltrion competing for a share of the KRW 43 trillion Keytruda market through strategic positioning.
By clearly presenting SB27's clinical results and domestic market approval timeline, Samsung Bioepis has emphasized therapeutic efficacy and market outlook. This offers cancer patients more treatment options while also potentially reducing healthcare costs.
Frequently Asked Questions
Does SB27 provide the same therapeutic effect as Keytruda?
Yes. SB27 has demonstrated equivalent therapeutic efficacy to Keytruda in Phase 1 and Phase 3 clinical trials.
What is Samsung Bioepis' SB27 market approval application timeline?
On August 10, 2026, Samsung Bioepis completed its domestic market approval application for SB27.
What is Samsung Bioepis' competitive strategy after Keytruda's patent expiration?
With SB27, Samsung Bioepis aims to secure a leading position in the Keytruda market while strengthening R&D investments to develop next-generation therapies.
Frequently Asked Questions
Samsung Bioepis' SB27 is a biosimilar to Keytruda, having demonstrated equivalence in Phase 1 and Phase 3 clinical trials. On August 10, 2026, it completed its domestic market approval application for the KRW 43 trillion market ahead of Keytruda's patent expiration, competing with Celltrion. Samsung Bioepis aims to secure therapeutic efficacy and market share through SB27 while strengthening R&D investments for next-generation therapy development.
Following Keytruda's patent expiration, it will be closely watched whether SB27 can establish itself as a substitute for Keytruda. Through this, Samsung Bioepis aims to provide cancer patients with new treatment options and potentially reduce healthcare costs.
The success of Samsung Bioepis' SB27 development is expected to enhance the competitiveness of South Korea's biotechnology industry while also positioning the company strongly in the global market. This is viewed as a significant event heralding innovative changes in the field of cancer treatment.
You can view similar articles on this topic all at once.
View Related ArticlesFAQ
Does SB27 provide the same therapeutic effect as Keytruda?
Yes. SB27 has demonstrated equivalent therapeutic efficacy to Keytruda in Phase 1 and Phase 3 clinical trials.
What is Samsung Bioepis' SB27 market approval application timeline?
On August 10, 2026, Samsung Bioepis completed its domestic market approval application for SB27.
What is Samsung Bioepis' competitive strategy after Keytruda's patent expiration?
With SB27, Samsung Bioepis aims to secure a leading position in the Keytruda market while strengthening R&D investments to develop next-generation therapies.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 삼성바이오에피스 키트루다 암 치료 효과: 치료 과정과 결과